InvestorLens

CRNX — CRINETICS PHARMACEUTICALS IN

Public company

Sign in to save2 tracked investors reported this
For educational research only.InvestorLens analyzes public regulatory filings (SEC EDGAR, STOCK Act PTRs) that may be delayed by 45 days or more. Information shown is historical and is not financial, legal, or tax advice, nor a recommendation or solicitation to buy or sell any security. Always do your own research.

InvestorLens aggregates public filing data to show which tracked investors reported holdings in this stock. Dollar values represent reported position values, not market capitalization, and may be delayed up to 45 days. Not a recommendation.

Sourced from SEC EDGAR public filings

Why are billionaires buying CRNX?

Built from public SEC filings and public economic data. Not a recommendation.

Confidence
50
Institutional Conviction
Net distribution · 1 buying vs 1 selling last quarter
35
Macro Tailwind
Macro conditions are mixed for this sector
57
Why? — Evidence & Confidence ▾

Of 2 tracked investors who changed their CRNX position last quarter, 1 bought and 1 sold (50% buy-side). Macro conditions are mixed for this sector (Macro Tailwind 57/100 in a Contraction regime).

Supporting evidence
  • +1 tracked investor added or increased positions last quarter (Steve Cohen)
  • +2 tracked investors reported holding CRNX at their latest filing
  • +Macro Health is 57/100 in a Contraction regime — historically acceptable for this sectorsource
Contradicting evidence — always shown
  • −1 tracked investor reduced or exited last quarter (0 reduced, 1 sold out)
  • −13F data is disclosed up to 45 days after quarter end — positions may have changed since
Know the limits
  • · 13F disclosure lag (up to 45 days)
  • · Tracked investors are a sample, not the whole market
  • · Sector regime fit is a historical average, not a guarantee

Every InvestorLens score shows its evidence — including what argues against it. Model conviction-v1 · generated 9/6/2026.

About CRINETICS PHARMACEUTICALS IN (CRNX)

CRINETICS PHARMACEUTICALS IN (CRNX) appears in the most recent 13F filings of 2 tracked institutional investors. The largest disclosed position is held by Steve Cohen (Point72 Asset Management), valued at $143M. Across recent filings, tracked investors recorded 4 new positions, 4 increased, 3 reduced, and 3 exited. All data sourced from SEC 13F filings.

Smart Money Consensus™

Based on recent institutional activity in CRNX

57
/100
Mixed Activity
Added / Increased8
Reduced3
Exited3
BearishBullish
Crowded Trade Score™

How many top investors track CRNX

13
/100
Undiscovered
2investors

Only 2 tracked investors report this position.

UndiscoveredCrowded
151015+

CRNX Ownership Composition

How CRINETICS PHARMACEUTICALS IN is held across tracked investor types, based on reported 13F positions.

Dominant Type
Multi-Strategy / Quant
100% of tracked value
Institutions
2
tracked investors
Total Reported
$7.9M
combined 13F value
Types1
  • Multi-Strategy / Quant100.0%
Multi-Strategy / Quant(2)
100.0%

Tracked investors currently reporting CRNX

3 tracked investors have since exited this position — listed separately below.

  • Steve CohenJun 30, 2026
    Point72 Asset Management
    Shares
    46.4K
    Value
    $1.7M
    % Portfolio
    0.00%
  • Ken GriffinJun 30, 2026
    Citadel Advisors
    Shares
    163.6K
    Value
    $6.1M
    % Portfolio
    0.00%

Previously held CRNX

These investors reported CRNX in an earlier quarter but not in their most recent 13F. Figures below are their last reported position, not a current holding.

InvestorFirmLast reported sharesValue thenLast held
Stanley DruckenmillerDuquesne Family Office122.7K$6.3MDec 31, 2024
Izzy EnglanderMillennium Management62.4K$2.3MMar 31, 2026
Paul Tudor JonesTudor Investment Corp46K$1.7MMar 31, 2026

Recent activity

Frequently asked questions

How many institutional investors hold CRNX?
2 tracked institutional investors disclosed a position in CRNX (CRINETICS PHARMACEUTICALS IN) in their most recent 13F filing.
Who is the largest institutional holder of CRNX?
Steve Cohen, Point72 Asset Management, holds the largest disclosed position in CRNX, valued at $143M.
Did institutional ownership of CRNX increase or decrease?
Across recent 13F filings, tracked investors recorded 4 new positions, 4 increased, 3 reduced, and 3 fully exited CRNX.
Where does this CRNX ownership data come from?
SEC Form 13F-HR filings, accessed via EDGAR. 13F filings are disclosed quarterly with a 45-day reporting delay and cover U.S.-listed long equity positions only. This is not investment advice.
CRNX (CRINETICS PHARMACEUTICALS IN) — Institutional Holders — InvestorLens